natgillin/translations-raw huggingface dataset:
Imidlertid er det på grund af manglen på interaktionsforsøg med andre NSAID’er ikke umiddelbart klart, om der er øget risiko for gastrointestinal blødning med alle NSAID- præparater.
However, due to the lack of interaction studies with other NSAIDs it is presently unclear whether there is an increased risk of gastrointestinal bleeding with all NSAIDs.
Imidlertid er det på grund af manglen på interaktionsforsøg med andre NSAID’er ikke umiddelbart klart, om der er øget risiko for gastrointestinal blødning med alle NSAID-præparater.
However, due to the lack of interaction studies with other NSAIDs it is presently unclear whether there is an increased risk of gastrointestinal bleeding with all NSAIDs.
Imidlertid er det på grund af manglen på interaktionsstudie med andre NSAID’er ikke umiddelbart klart, om der er øget risiko for gastrointestinal blødning med alle NSAID- præparater.
However, due to the lack of interaction studies with other NSAIDs it is presently unclear whether there is an increased risk of gastrointestinal bleeding with all NSAIDs.
Imidlertid er det på grund af manglen på interaktionsstudie med andre NSAID’er ikke umiddelbart klart, om der er øget risiko for gastrointestinal blødning med alle NSAID-præparater.
However, due to the lack of interaction studies with other NSAIDs it is presently unclear whether there is an increased risk of gastrointestinal bleeding with all NSAIDs.
Imidlertid er det på grund af manglen på interaktionsstudier med andre NSAID’er ikke umiddelbart klart, om der er øget risiko for gastrointestinal blødning med alle NSAID- præparater.
However, due to the lack of interaction studies with other NSAIDs it is presently unclear whether there is an increased risk of gastrointestinal bleeding with all NSAIDs.
Imidlertid er det på grund af manglen på interaktionsstudier med andre NSAID’er ikke umiddelbart klart, om der er øget risiko for gastrointestinal blødning med alle NSAID-præparater.
However, due to the lack of interaction studies with other NSAIDs it is presently unclear whether there is an increased risk of gastrointestinal bleeding with all NSAIDs.
Imidlertid er det på grund af manglen på interaktionsstudier med andre NSAID’er ikke umiddelbart klart, om der er øget risiko for gastrointestinal blødning med alle NSAID’er.
However, due to the lack of interaction studies with other NSAIDs it is presently unclear whether there is an increased risk of gastrointestinal bleeding with all NSAIDs.
Imidlertid er kemisk og fysisk stabilitet under brug blevet påvist i 8 timer ved 2 °C-8 °C i den originale emballage og beskyttet mod kraftigt lys.
However, chemical and physical in use stability has been demonstrated for 8 hours at 2°C-8°C in the original carton, and protected from bright light.
Imidlertid er kemisk og fysisk stabilitet under brug blevet påvist i 8 timer ved temperaturer på 2 °C-8 °C i den originale emballage og beskyttet mod kraftigt lys.
However, chemical and physical in use stability has been demonstrated for 8 hours at 2°C-8°C in the original carton, and protected from bright light.
Imidlertid er PD-L1-biomarkørens rolle ikke fuldt belyst.
However, the role of this biomarker (tumour PD-L1 expression) has not been fully elucidated.
Imidlertid er PET ikke almindeligt tilgængeligt i Europa.
However PET is not widely available throughout Europe.
Imidlertid er virkning ved IntronA i kombination med ribavirin er blevet undersøgt hos børn og unge, der ikke tidligere har været behandlet for kronisk hepatitis C.
The efficacy and safety of IntronA in combination with ribavirin has been studied in children and adolescents who have not been previously treated for chronic hepatitis C.
Imidlertid er virkningen af tidlig behandling med AVONEX uvis selv i denne høj-risiko undergruppe, da studiet hovedsageligt var designet til at bestemme tidspunktet for et nyt anfald frem for langtidsudviklingen af sygdommen.
However, the impact of early treatment with AVONEX is unknown even in this high-risk subgroup as the study was mainly designed to assess the time to the second event rather than the long term evolution of the disease.
Imidlertid fik de patienter, som indgik i kliniske forsøg med clopidogrel, en lang række ledsagende lægemidler såsom diuretika, beta-blokkere, ACE-hæmmere, calcium- antagonister, kolesterolsænkende midler, dilatatorer med effekt på koronarkarrene, antidiabetika (inklusive insulin), antiepileptika samt GPIIb/IIIa-hæmmere, uden at der blev påvist klinisk signifikante uønskede interaktioner.
However, patients entered into clinical trials with clopidogrel received a variety of concomitant medicinal products including diuretics, beta blockers, ACEI, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.
Imidlertid fik de patienter, som indgik i kliniske forsøg med clopidogrel, en lang række ledsagende lægemidler såsom diuretika, beta-blokkere, ACE-hæmmere, calcium- antagonister, kolesterolsænkende midler, dilatatorer med effekt på koronarkarrene, antidiabetika (inklusive insulin), antiepileptika samt GPIIb/IIIa-hæmmere, uden at der blev påvist klinisk signifikante uønskede interaktioner.
However, patients entered into clinical trials with clopidogrel received a variety of concomitant medicinal products including diuretics, beta blockers, ACEI, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.
Imidlertid fik de patienter, som indgik i kliniske forsøg med clopidogrel, en lang række ledsagende lægemidler såsom diuretika, beta-blokkere, ACE-hæmmere, calciumantagonister, kolesterolsænkende midler, dilatatorer med effekt på koronarkarrene, antidiabetika (inklusive insulin), antiepileptika samt GPIIb/IIIa- hæmmere, uden at der blev påvist klinisk signifikante uønskede interaktioner.
However, patients entered into clinical trials with clopidogrel received a variety of concomitant medicinal products including diuretics, beta blockers, ACEI, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.
Imidlertid fik de patienter, som indgik i kliniske forsøg med clopidogrel, en lang række ledsagende lægemidler såsom diuretika, beta-blokkere, ACE-hæmmere, calciumantagonister, kolesterolsænkende midler, dilatatorer med effekt på koronarkarrene, antidiabetika (inklusive insulin), antiepileptika samt GPIIb/IIIa- hæmmere, uden at der blev påvist klinisk signifikante uønskede interaktioner.
However, patients entered into clinical trials with clopidogrel received a variety of concomitant medicinal products including diuretics, beta blockers, ACEI, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.
Imidlertid fik de patienter, som indgik i kliniske forsøg med clopidogrel, en lang række ledsagende lægemidler såsom diuretika, betablokkere, ACE-hæmmere, calcium- antagonister, kolesterolsænkende midler, dilatatorer med effekt på koronarkarrene, antidiabetika (inklusive insulin), antiepileptika samt GPIIb/IIIa-hæmmere, uden at der blev påvist klinisk signifikante uønskede interaktioner.
However, patients entered into clinical trials with clopidogrel received a variety of concomitant medicinal products including diuretics, beta blockers, ACEI, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.
Imidlertid fik de patienter, som indgik i kliniske forsøg med clopidogrel, en lang række ledsagende lægemidler, såsom diuretika, beta-blokkere, ACE-hæmmere, calciumantagonister, kolesterolsænkende midler, dilatatorer med effekt på koronarkarrene, antidiabetika (inklusive insulin), antiepileptika samt GPIIb/IIIa-hæmmere, uden at der blev påvist klinisk signifikante uønskede interaktioner.
However, patients entered into clinical trials with clopidogrel received a variety of concomitant medicinal products including diuretics, beta blockers, ACEI, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.
Imidlertid fik de patienter, som indgik i kliniske studier med clopidogrel, en lang række ledsagende lægemidler såsom diuretika, beta-blokkere, ACE-hæmmere, calcium- antagonister, kolesterolsænkende midler, dilatatorer med effekt på koronarkarrene, antidiabetika (inklusive insulin), antiepileptika samt GPIIb/IIIa-hæmmere, uden at der blev påvist klinisk signifikante uønskede interaktioner.
However, patients entered into clinical trials with clopidogrel received a variety of concomitant medicinal products including diuretics, beta blockers, ACEI, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.
Imidlertid fik de patienter, som indgik i kliniske studier med clopidogrel, en lang række ledsagende lægemidler såsom diuretika, beta-blokkere, ACE-hæmmere, calcium- antagonister, kolesterolsænkende midler, dilatatorer med effekt på koronarkarrene, antidiabetika (inklusive insulin), antiepileptika samt GPIIb/IIIa-hæmmere, uden at der blev påvist klinisk signifikante uønskede interaktioner.
However, patients entered into clinical trials with clopidogrel received a variety of concomitant medicinal products including diuretics, beta blockers, ACEI, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.
Imidlertid fik de patienter, som indgik i kliniske studier med clopidogrel, en lang række ledsagende lægemidler såsom diuretika, beta-blokkere, ACE-hæmmere, calciumantagonister, kolesterolsænkende midler, dilatatorer med effekt på koronarkarrene, antidiabetika (inklusive insulin), antiepileptika samt GPIIb/IIIa- hæmmere, uden at der blev påvist klinisk signifikante uønskede interaktioner.
However, patients entered into clinical trials with clopidogrel received a variety of concomitant medicinal products including diuretics, beta blockers, ACEI, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.
Imidlertid fik de patienter, som indgik i kliniske studier med clopidogrel, en lang række lægemidler samtidigt, såsom diuretika, beta-blokkere, ACE-hæmmere, calcium- antagonister, kolesterolsænkende midler, dilatatorer med effekt på koronarkarrene, antidiabetika (inklusive insulin), antiepileptika samt GPIIb/IIIa-hæmmere, uden at der blev påvist klinisk signifikante uønskede interaktioner.
However, patients entered into clinical trials with clopidogrel received a variety of concomitant medicinal products including diuretics, beta blockers, ACEI, calcium antagonists, cholesterol lowering agents, coronary vasodilators, antidiabetic agents (including insulin), antiepileptic agents, and GPIIb/IIIa antagonists without evidence of clinically significant adverse interactions.
Imidlertid har samtidig behandling af køer med tylosin og Velactis ikke vist ændringer af cabergolins farmakokinetiske egenskaber.
However, administration of tylosin concomitantly with Velactis in cows did not show any changes of Velactis pharmacokinetic properties.
Imidlertid har sikkerhedsforsøg i laboratorium vist, at brugen af COXEVAC i handyr er sikkert.
However, in safety laboratory trials, the use of COXEVAC in males proved to be safe.
Imidlertid har sikkerhedsforsøg i laboratorium vist, at brugen af Coxevac i handyr er sikkert.
However, in safety laboratory trials, the use of the vaccine in males proved to be safe.
Imidlertid havde syv ud af 13 patienter (54 %) i de placebo-kontrollerede afprøvninger, som opnåede isolater med MIC’er på 128 µg/ml under brug af TOBI, forbedring af lungefunktionen.
However, seven of 13 patients (54%) in the placebo-controlled trials who acquired isolates with MICs of 128 µg/ml while using TOBI had improvement in pulmonary function.
Imidlertid kan det ikke forudsiges hvornår næste brunst vil indtræde.
However, the timing of return to heat cannot be predicted.
Imidlertid kan det ikke forudsiges, hvornår næste brunst vil indtræde.
However, the timing of return to heat cannot be predicted.
Imidlertid kan hepatisk sygdom med overvejende biliær skade som f.eks. primær biliær cirrh vise en anden virkning.
However, hepatic disease with predominantly biliary damage, such as primary biliary cirrhosis, may show a different effect.
Imidlertid kan man i visse tilfælde ikke udelukke Aptivus’ rolle.
However, in some cases the role of Aptivus cannot be excluded.
Imidlertid kan man i visse tilfælde ikke udelukke tipranavir’s rolle.
However, in some cases the role of tipranavir cannot be excluded.
Imidlertid ophørte flere patienter i sitagliptingruppen en i glipizidgruppen med behandling på grund af manglende effekt.
However, more patients in the sitagliptin group discontinued due to lack of efficacy than in the glipizide group.
Imidlertid skal der ved den behandlingsfri periode tages hensyn til de farmakokinetiske egenskaber af de produkter, der er brugt tidligere.
The treatment-free period, however, should take into account the pharmacokinetic properties of the products used previously.
Imidlertid skal der ved den behandlingsfri periode tages hensyn til optagelsen af de produkter, der er brugt tidligere.
The treatment-free period, however, should take into account the pharmacokinetic properties of the products used previously.
Imidlertid tyder in vitro- elektrofysiologiske studier på, at både eslicarbazepinacetat og dets metabolitter stabiliserer de spændingsafhængige natriumkanalers inaktive tilstand og forhindrer dem i at blive reaktiveret med fortsat repetitiv neuronal fyring til følge.
However, in vitro electrophysiological studies indicate that both eslicarbazepine acetate and its metabolites stabilise the inactivated state of voltage-gated sodium channels, preventing their return to the activated state and thereby sustaining repetitive neuronal firing.
Imidlertid udgjorde køn og alder ikke signifikante faktorer for den gennemsnitlige plasma- clearance efter justering for kreatininclearance og kropsvægt.
However, after adjusting for creatinine clearance and body weight, gender and age were not significant factors for mean plasma clearance.
Imidlertid udøves den væsentligste antivirale aktivitet gennem inkorporering af monophosphatformen i den virale DNA- kæde, hvorved kædedannelsen afsluttes.
However, their main antiviral activity is through incorporation of the monophosphate form into the viral DNA chain, resulting in chain termination.
Imidlertid var antallet af patienter i undersøgelsen for få til at bevise, hvorvidt en sådan kombineret behandling er lige så effektiv som deferoxamin taget alene.
However, there were too few patients in the study to prove whether or not such a schedule is as effective as deferoxamine taken on its own.
Imidlertid var der ingen signifikant forskel i vedligeholdelsesfasen.
However there was no significant difference during the maintenance phase.
Imidlertid var middelværdien af MPAG-AUC efter en enkelt dosis 3-6 gange højere hos personer med svært nedsat nyrefunktion end hos personer med let nedsat nyrefunktion eller normale, sunde personer svarende til den kendte renale udskillelse af MPAG.
However, the mean single dose MPAG AUC was 3 – 6-fold higher in subjects with severe renal impairment than in subjects with mild renal impairment or normal healthy subjects, consistent with the known renal elimination of MPAG.
Imidlertid var middelværdien af MPAG-AUC efter en enkelt dosis3-6 gange højere hos personer med svært nedsat nyrefunktion end hos personer med let nedsat nyrefunktion eller normale, sunde personer svarende til den kendte renale udskillelse af MPAG.
However, the mean single dose MPAG AUC was 3 – 6-fold higher in subjects with severe renal impairment than in subjects with mild renal impairment or normal healthy subjects, consistent with the known renal elimination of MPAG.
Imidlertid var middelværdien af MPAG-AUC efter en enkeltdosis 3-6 gange højere hos personer med svært nedsat nyrefunktion end hos personer med let nedsat nyrefunktion eller normale, sunde personer svarende til den kendte renale udskillelse af MPAG.
However, the mean single dose MPAG AUC was 3 – 6 fold higher in subjects with severe renal impairment than in subjects with mild renal impairment or normal healthy subjects, consistent with the known renal elimination of MPAG.
Imidlertid var middelværdien afMPAG-AUC efter en enkelt dosis 3-6 gange højere hos personer med svært nedsat nyrefunktion end hos personer med let nedsat nyrefunktion eller normale, sunde personer svarende til den kendte renale udskillelse af MPAG.
However, the mean single dose MPAG AUC was 3 – 6-fold higher in subjects with severe renal impairment than in subjects with mild renal impairment or normal healthy subjects, consistent with the known renal elimination of MPAG.
Imidlertid var størstedelen af de hyppigst forekommende bivirkninger milde til moderate de indtrådte typisk i starten af behandlingen, og de fleste bivirkninger aftog ved fortsat behandling.
However, the majority of common adverse reactions were mild to moderate, they usually started early in therapy, and most tended to subside even as therapy was continued.
Imidlertid viser de kliniske og prækliniske sikkerhedsdata sig at være veltolererede og sikre under kronisk administration
However, clinical and non-clinical safety data show it to be well-tolerated and safe during chronic administration
Imidlertid øger brugen af sevofluran til mennesker både intensiteten og varigheden af den neuromuskulære blokade fremkaldt af non-depolariserende muskelrelaksantia.
However, in humans the use of sevoflurane increases both the intensity and duration of neuromuscular blockade induced by nondepolarising muscle relaxants.
Imiglucerase (rekombinant makrofag-målrettet ß-glucosidasesyre) erstatter den manglende enzym- aktivitet, hydrolyserer glucosylceramid og korrigerer dermed den indledende patofysiologi og forhindrer sekundær patologi.
Imiglucerase (recombinant macrophage targeted acid ß-glucosidase) replaces the deficient enzyme activity, hydrolysing glucosylceramide, thus correcting initial pathophysiology and preventing secondary pathology.
Imiglucerase er en modificeret form af det humane enzym - glucosidasesyre fremstillet ved rekombinant DNA-teknologi.
Imiglucerase is a modified form of the human enzyme acid -glucosidase produced by recombinant DNA technology.
imiglucerase i 9
group (N=39)
imiglucerase-behandling
imiglucerase
Imiquimod creme bør anvendes inden normal sengetid.
Imiquimod cream should be applied prior to normal sleeping hours.
Imiquimod creme skal påføres i et tyndt lag og gnides på det rene vorteområde, indtil cremen er trængt ind.
Imiquimod cream should be applied in a thin layer and rubbed on the clean wart area until the cream vanishes.
Imitanib Accord anvendes også til behandling af voksne med:
Imatinib Accord is a treatment for adults for:
Imitanib Accord er en behandling til voksne og børn mod:
Imatinib Accord is a treatment for:
Imitanib Accord er et lægemiddel, der indeholder et aktivt stof kaldet imatinib.
Imatinib Accord is a medicine containing an active substance called imatinib.
Imlygic 106 PFU/ml injektionsvæske talimogene laherparepvec Intralæsional anvendelse
Imlygic 106 PFU/mL injection talimogene laherparepvec Intralesional use
Imlygic 106 plaquedannende enheder (PFU)/ml injektionsvæske, opløsning
Imlygic 106 plaque forming units (PFU)/mL solution for injection
Imlygic 106 plaquedannende enheder (PFU)/ml injektionsvæske, opløsning Imlygic 108 plaquedannende enheder (PFU)/ml injektionsvæske, opløsning talimogen laherparepvec
Imlygic 106 plaque forming units (PFU)/mL solution for injection Imlygic 108 plaque forming units (PFU)/mL solution for injection talimogene laherparepvec
Imlygic 106 plaquedannende enheder (PFU)/ml injektionsvæske, opløsning talimogene laherparepvec
Imlygic 106 plaque forming units (PFU)/mL solution for injection talimogene laherparepvec
Imlygic 108 PFU/ml injektionsvæske talimogene laherparepvec Intralæsional anvendelse
Imlygic 108 PFU/mL injection talimogene laherparepvec Intralesional use
Imlygic 108 plaquedannende enheder (PFU)/ml injektionsvæske, opløsning
Imlygic 108 plaque forming units (PFU)/mL solution for injection
Imlygic 108 plaquedannende enheder (PFU)/ml injektionsvæske, opløsning talimogene laherparepvec
Imlygic 108 plaque forming units (PFU)/mL solution for injection talimogene laherparepvec
Imlygic anvender melanomcellernes eget system til at formere sig, så det til sidst overvinder melanomcellerne og dræber dem.
Imlygic uses the melanoma cells’ own machinery to multiply, eventually overwhelming melanoma cells and killing them.
Imlygic er et lægemiddel til avanceret terapi, som kaldes et "genterapiprodukt".
Imlygic is a type of advanced therapy medicine called a ‘gene therapy product’.
Imlygic indeholder cirka 30 mg (1,3 mmol) natrium i hver dosis på 4 ml.
Imlygic contains approximately 30 mg (1.3 mmol) sodium in each 4 mL dose.
Imlygic indeholder sorbitol (E420).
Imlygic contains sorbitol (E420).
Imlygic kan forårsage autoimmune reaktioner (en overreaktion i kroppens immunsystem).
Imlygic may cause autoimmune reactions (an over-reaction of the body’s immune system).
Imlygic kan indtræde i raske celler, men er ikke beregnet til at formere sig i dem.
Although Imlygic can enter healthy cells, it is not designed to multiply inside them.
Imlygic kan medføre infektion på injektionsstedet.
Imlygic may cause infection at the injection site.
Imlygic må ikke nedfryses igen, når først det er optøet.
Imlygic must not be refrozen once it has thawed.
Imlygic skal efter optøning administreres så hurtigt som praktisk muligt.
After thawing, administer Imlygic as soon as practically feasible.
Imlygics sporbarhed
Traceability of Imlygic
Immun medieret hæmolytisk anæmi*
Immune mediated haemolytic anaemia
immun trombocytopenisk purpura (ITP), hæmolytisk anæmi
immune thrombocytopenic purpura, haemolytic anaemia
Immun trombocytopenisk purpura, trombocytopeni, nedsat hæmoglobin, nedsat hæmatokrit
Immune thrombocytopenic purpura, thrombocytopenia haemoglobin decreased, haematocrit decreased
Immun-
Cataract
Immun-
Immuno
Immun- systemet
Body System
Immun- systemet
Gastrointestinal disorders
Immun- systemet
Immune system disorders
immun-allergisk
c system
Immun-medieret hæmolytisk anæmi
Immune-mediated haemolytic anaemia
Immun-medieret hæmolytisk anæmi (antistof-medieret ødelæggelse af de røde blodlegemer)
Immune mediated haemolytic anaemia (antibody-mediated destruction of red blood cells)
Immun-medieret hæmolytisk anæmi (antistof-medieret ødelæggelse af de røde blodlegemer)
immune-mediated haemolytic anaemia (antibody-mediated destruction of red blood cells)
immun-reaktiveringssyndrom
immune reactivation syndrome
Immundefekt.
Immunodeficiency.
Immunerelateret colitis
Immune-related colitis
Immunerelateret nefritis og nedsat nyrefunktion
Immune-related nephritis and renal dysfunction
Immunerespons mod A/Vietnam/1194/2004
Immune response to A/Vietnam/1194/2004